 |
|
PAPNET-Assisted Rescreening of Cervical Smears
Cost and Accuracy Compared With a 100% Manual Rescreening Strategy
Timothy J. O'Leary, MD, PhD;
Miguel Tellado, MD;
Sally-Beth Buckner, SCT, (ASCP);
Izzat S. Ali, CT, (ASCP);
Angelica Stevens, CT, (ASCP);
Curtis W. Ollayos, MD
JAMA. 1998;279:235-237.
Context.— The Food and Drug Administration has recently approved several devices that use computerized image analysis to rescreen Papanicolaou (Pap) smears that have already been examined by cytotechnologists. Physicians and laboratories must decide whether the utility of these devices justifies the cost.
Objective.— To determine the effectiveness and cost of PAPNET-assisted rescreening in identifying cervical abnormalities not identified by manual rescreening.
Design.— PAPNET-assisted rescreening of 5478 Pap smears obtained in 1994 and 1995 previously identified as "within normal limits" or "benign changes" on both initial and random screening.
Patients.— Female service members and dependents aged 12 to 88 years.
Setting.— Air Force clinics in the United States and Japan.
Intervention.— Rescreening of Pap smears by PAPNET, followed by reevaluation of abnormal smears by the consensus panel, consisting of 3 cytotechnologists and 3 pathologists.
Main Outcome Measures.— Proportion of Pap smears initially screened as normal identified as abnormal by both PAPNET and consensus panel; costs of rescreening.
Results.— PAPNET screening identified 1614 (29%) slides requiring additional microscopic review. On further review, 448 (8% of total) had possibly abnormal cells. Ultimately, 11 of these cases were reviewed by the consensus panel for potentially atypical cells. Of these 11 cases, 5 were reclassified as atypical squamous cells of undetermined significance (ASCUS) and 1 as atypical glandular cells of undetermined significance (AGUS). No additional squamous intraepithelial neoplasia (SIL) was identified in these smears; the patient with a diagnosis of AGUS on rescreening was diagnosed as having a low-grade SIL (LSIL) on follow-up. Costs were $5825 to $33781 for each additional ASCUS or AGUS diagnosis. A cost of $17475 to $101343 is expected for each case of LSIL identified by PAPNET-assisted rescreening and not by traditional manual rescreening.
Conclusions.— PAPNET-assisted rescreening identified a few more cases of ASCUS than did manual rescreening, but at a relatively high cost. The costs of rescreening should be carefully compared with the expected efficacy in reducing cervical cancer mortality.
From the Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, DC.
RELATED ARTICLE
Making the Most of Pap Testing
Alan M. Garber
JAMA. 1998;279(3):240-241.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Predicting the Presence of Acute Pulmonary Embolism: A Comparative Analysis of the Artificial Neural Network, Logistic Regression, and Threshold Models
Eng
Am. J. Roentgenol. 2002;179:869-874.
ABSTRACT
| FULL TEXT
Cost-effectiveness of 3 Methods to Enhance the Sensitivity of Papanicolaou Testing
Brown and Garber
JAMA 1999;281:347-353.
ABSTRACT
| FULL TEXT
Reducing Mortality Due to Cervical Cancer: PAPNET Fails the Test
Melnikow and Nuovo
Arch Fam Med 1999;8:56-57.
FULL TEXT
Rescreening of Cervical Papanicolaou Smears Using PAPNET
Greenberg et al.
JAMA 1998;279:1785-1788.
FULL TEXT
AUTOMATED CERVICAL CYTOLOGY: IS IT REALLY BETTER?
JWatch General 1998;1998:8-8.
FULL TEXT
Making the Most of Pap Testing
Garber
JAMA 1998;279:240-241.
FULL TEXT
|
